期刊文献+

AFP与DKK1联合检测对原发性肝癌的诊断价值 被引量:8

Diagnostic value of combined detection of AFP and DKK1 in primary hepatic carcinoma
下载PDF
导出
摘要 目的探讨血清Dickkopf同源物1(DKK1)、甲胎蛋白(AFP)单独或联合检测原发性肝癌的临床意义。方法收集27例原发性肝癌患者(原发性肝癌组)、43例肝硬化患者(肝硬化组)的血清进行检测,采用酶联免疫吸附试验检测血清DKK1浓度,采用电化学发光免疫法检测血清AFP浓度,应用Logistic回归和ROC曲线进行分析,建立原发性肝癌诊断的预测模型。结果原发性肝癌组血清AFP、DKK1水平明显高于肝硬化组;AFP和DKK1单独检测的灵敏度分别为55.6%和77.8%,特异度均为88.4%;二者联合检测的灵敏度为81.5%,特异度为93.0%,特异度明显高于单项指标检测结果,差异有统计学意义(P<0.05)。AFP和DKK1的ROC曲线下面积(AUC)分别为0.849和0.893,二者联合检测的AUC为0.935。结论血清DKK1可作为诊断原发性肝癌的血清标志物,联合AFP可提高诊断效能,在原发性肝癌诊断中具有重要的临床价值。 Objective To investigate the clinical significance of single and combined detection of Dickkopf-1(DKK1) and alpha fetoprotein(AFP) in the diagnosis of primary hepatic carcinoma(PHC).Methods Serum samples were collected from 27 patients with primary hepatic carcinoma and 43 patients with hepatocirrhosis.The serum level of DKK1 was detected by enzyme-linked immunosorbent assay(ELISA),while the serum level of AFP was detected by electroch emiluminescence immunoassay(ECLIA).Logistic regression and ROC curve were utilized to analyze,furthermore,to set up prediction models for the diagnosis of primary hepatic carcinoma.Results The serum level of AFP and DKKI in patients with PHC were higher than those with hepatocirrhosis.The sensitivity of AFP and DKK1 was 55.6% and 77.8% respectively,the specificity of both was 88.4%.In contrast,the sensitivity of combined detection was 81.5%,specificity was up to 93.0%,significantly higher than single detection.The area under the ROC curve(AUC) of AFP and DKK1 was 0.849 and 0.893 in turn,and the AUC of combined detection was 0.935.Conclusion DKK1 can be used as serum marker for the diagnosis of PHC,and the combined determination of DKK1 and AFP can improve diagnostic performance,which shows important clinic value in diagnosis of primary hepatic carcinoma.
出处 《中国现代医药杂志》 2017年第10期1-3,共3页 Modern Medicine Journal of China
基金 2014年株洲市科技计划项目
关键词 原发性肝癌 甲胎蛋白 DKK1 Primary hepatic carcinoma Alpha-fetoprotein Dickkopf-1
  • 相关文献

参考文献3

二级参考文献21

  • 1Qiujin Shen*, Jia Fan*, Xin-Rong Yang*, Yexiong Tan*, Weifeng Zhao*,Wenxin Qin.et al Serum DKK1 as a protein biomarker for the diagnosis ofhepatocellular carcinoma: a large-scale, multicentre study. www.thelancet.com/oncology Published online June 26, 2012 http://dx.doi.org/10.1016/S 1470-2045 ( 12)70233 -4. 被引量:1
  • 2Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012 [J]. CA Cancer J Clin, 2015, 65(2):87-108. 被引量:1
  • 3International Agency for Reseawh on Cancer. GLOBOCAN 2012: estimated t'ancer incidence, mortality and prevalence worldwide in 2012,2014[ EB/OL]. [ 2014-12-16]. http://globocan.iarc.fr. 被引量:1
  • 4.l'eii,'()M i'rkif-DM, Macle,,na,, R, et al. Cancer registration principles and methods IARC Sci Pub No.95 [ M ]. Lyon: IARC, 1991:101-107. 被引量:1
  • 5Parkin DM, Chert VW, Ferlay J, et al. Comparability and quality control in cancer registration. IARC Technical Report No. 19 [ J ]. l.yon: IARC, 1994:35-49. 被引量:1
  • 6Parkin DM, Bray F. Evaluation of data quality in the cancer registry. : principles and methxls Part I1. Completeness[ J ]. Eur J Cancer, 2009, 45 ( 5 ) : 756-764. 被引量:1
  • 7Bray F, Pu'kin DM. Evaluation of data quality in the cmlcer registry : principles and methods. Part 1: comparability, validity and limeliness[ J ]. Eur J Cancer, 2(108, 45(5) :747-755. 被引量:1
  • 8Zeng H, Zheng R, Guo Y, et al. Cancer survival in China, 2003- 2005: a population-based study [J]. lnt J Cancer. 2015. 136 (8) : 1921-1930. 被引量:1
  • 9Kim H J, Fay MP, Feuer EJ, el al. Permutation tests for joinpoint regression with applications to cancer rates [ J ]. Stat Med, 2000, 19(3) :335-351. 被引量:1
  • 10David Yiu-Kuen But,Ching-Lung Lai,Man-Fung Yuen.Natural history of hepatitis-related hepatocellular carcinoma[J].World Journal of Gastroenterology,2008,14(11):1652-1656. 被引量:58

共引文献273

同被引文献94

引证文献8

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部